Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

Negulescu says the company’s high-throughput screening, which uses fast detectors to locate dyes that indicate compounds that inhibit sodium channels, can perform up to 50,000 tests per day.

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Eli Lilly is expanding its efforts to advance next-generation pain medications. | Eli Lilly is expanding its efforts to ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which ...

an investigational NaV1.8 pain signal inhibitor. Channel's Chief Medical Officer, Eric Lang, highlighted the distinctions between NaV1.7 and NaV1.8 sodium channels, noting that NaV1.7, which plays ...

There were no serious adverse events related to the NaV 1.8 inhibitor, according to Bertoch. During the ASA session Q&A, he acknowledged the cardiac concerns surrounding sodium channel inhibition ...

All of the sodium channels are closely related ... a small molecule designed to selectively inhibit NaV1.8. This drug was developed for acute pain, defined as pain lasting less than three months.

Praxis Precision Medicines has scored another midphase win in epilepsy this year, with its sodium channel inhibitor shown to reduce seizures in children with two specific types of the neurological ...

Halneuron, a NaV 1.7 sodium channel inhibitor, is being tested for chemotherapy-induced neuropathic pain, offering a potential opioid alternative. Previous trials showed Halneuron significantly ...

These studies "demonstrate the potential of the sodium channel inhibitor benzamil as a prototype for an effective, cost-efficient, and targeted therapeutic for skin inflammation," Marinkovich and ...

The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical ...